Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank21
3Y CAGR+5.1%
5Y CAGR-13.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+5.1%/yr
vs -23.2%/yr prior
5Y CAGR
-13.6%/yr
Recent acceleration
Acceleration
+28.3pp
Accelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 2.66 | +59.6% |
| 2024 | 1.67 | -30.4% |
| 2023 | 2.40 | +4.5% |
| 2022 | 2.29 | -26.2% |
| 2021 | 3.11 | -43.7% |
| 2020 | 5.52 | -12.0% |
| 2019 | 6.27 | -4.7% |
| 2018 | 6.58 | -93.5% |
| 2017 | 100.83 | +876.4% |
| 2016 | 10.33 | - |